<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="971">
  <stage>Registered</stage>
  <submitdate>22/12/2005</submitdate>
  <approvaldate>23/12/2005</approvaldate>
  <actrnumber>ACTRN12605000802606</actrnumber>
  <trial_identification>
    <studytitle>SHIRT (Salvage Hodgkins Immunoradiotherapy)</studytitle>
    <scientifictitle>A Pilot Study of Radioimmunotherapy with Iodine-131 Basiliximab Anti-CD25 Antibody for Relapsed or Refractory Hodgkins Disease and Other Lymphoproliferative Malignancies Expressing IL-2R</scientifictitle>
    <utrn />
    <trialacronym>SHIRT</trialacronym>
    <secondaryid>Single Centre Open-Label Non-Randomised Physician Sponsored Pilot Study</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lymphoproliferative Malignancies (Relapsed or Refractory)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Hodgkin's</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A Pilot Study of Radioimmunotherapy with Iodine-131 Basiliximab Anti-CD25 Antibody for Relapsed or Refractory Hodgkins Disease and Other Lymphoproliferetive Malignancies Expressing IL-2R</interventions>
    <comparator />
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Efficacy</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Progression Free Survival</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Refractory histologically proven lymphoma i.e. patients who have been treated with at least a first or second line conventional chemotherapy which may include ABMT/PBSCT and have subsequently relapsed.Lymphoproliferative malignancies immunohistocytochemically shown to express IL-2R (CD25)Measurable disease either clinically or radiologically by X-ray, CT, US or MRI or FDG PET scan.  Age =18 years.Life expectancy = 3 months.ECOG performance status &lt; 2No anti-lymphoma treatment in the previous 6 weeks (if on steroids a stable dosage over the same period is required).Haematological and biochemical indices:i) Absolute neutrophil count of =1.5 x 10^9 /litre.ii) Haemoglobin = 10g/dl.iii) Platelet count = 100 x 10^9/litre.iv) Plasma creatinine =150 µmol/l or GFR = 50ml/min.v) Plasma bilirubin = 30 µmol/l. vi) ALT/AST =2x upper limit of normal (5x upper limit of normal in the presence of liver metastases).vii) Thyroid function either normal or if the patient has a known thyroid abnormality, it must be stable on treatment.Signed written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Poor renal function (creatinine level &gt; 150µmol/l), poor hepatic function (total bilirubin level &gt; 30mmol/l, transaminases &gt; 2.5 maximum normal level) unless these abnormalities are related to the lymphoma.  Poor bone marrow reserve as defined by neutrophils &lt; 1.5 x 10^9/L or platelets &lt;100 x 10^9/L. Cardiac failure (NYHA class III-IV)Patients who are poor medical risks because of non-malignant systemic disease, as well as those with active uncontrolled infection.Documented infection with HIV, HBC, HHV8 and HBV (in the absence of vaccination)Central nervous system or meningeal involvement by lymphomaAny serious active disease or co-morbid condition (according to the investigators decision and information provided in the IDB).Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage O (in situ) cervical carcinomaTreatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the studyPregnant or lactating women, or women of child bearing potential in whom pregnancy cannot be excluded. Patients of child bearing/child fathering potential not using adequate medically approved contraception 4 weeks before, during the study and for six months afterwards.Adult patient unable to provide informed consent because of intellectual impairment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/03/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>South Metropolitan Area Health Service WA</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Physician Sponsored</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Fremantle Hospital and Health Service</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Radiolabelled antibody treatment of Hodgkin's disease and other lymphomas which have either not responded to conventional chemotherapy and/or radiotherapy, or which have relapsed following initial response to standard treatment.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Fremantle Hospital and Health Service</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Michael F Leahy</name>
      <address>Department of Haematology
Fremantle Hospital
Alma St
Fremantle WA 6160</address>
      <phone>+61 8 94312886</phone>
      <fax>+61 8 94312881</fax>
      <email>michael.leahy@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor J Harvey Turner</name>
      <address>Department of Nuclear Medicine
Fremantle Hospital
Alma St
Fremantle WA 6160</address>
      <phone>+61 8 94312888</phone>
      <fax>+61 8 94312889</fax>
      <email>harvey.turner@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>